SARS-CoV-2 humoral immune response in patients with cardiovascular risk factors: the COmmunity Cohort Study protocol

被引:4
|
作者
Bachelet, Vivienne C. [1 ]
Silva-Ayarza, Ignacio [1 ,2 ]
Lizana, Francisca J. [1 ]
Gomolan, Patricio [1 ]
Silva-Villalobos, Diego [1 ]
Navarrete, Maria S. [1 ]
机构
[1] Univ Santiago de Chile, Escuela Med, Santiago, Chile
[2] Hosp Barros Luco, Dept Infect Dis, Santiago, Chile
来源
BMJ OPEN | 2022年 / 12卷 / 05期
关键词
ANTIBODY-RESPONSES; DISEASE; DURABILITY; BNT162B2; COVID-19; KINETICS; VOCS;
D O I
10.1136/bmjopen-2022-061345
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction The COmmunity Cohort Study aims to determine, after natural exposure to SARS-CoV-2 or anti-SARS-CoV-2 vaccines deployed in Chile to prevent COVID-19 in the context of the current pandemic, the strength and duration of detectable neutralising antibodies in adult ambulatory primary care patients with cardiovascular risk factors. Methods and analysis We will set up a community-based longitudinal, prospective cohort study. The study will be conducted in two public outpatient clinics located in the southern district of Santiago, Chile. We expect to begin recruitment in the second quarter of 2022. Each patient will be followed up for at least 1 year after inclusion in the cohort. The eligible population will be adult patients registered in the Cardiovascular Health Programme. Exposure in this study is defined as any event where participants have contact with SARS-CoV-2 antigens from natural exposure or vaccination. The primary outcomes are seroconversion and strength and duration of the neutralising IgG antibodies to SARS-CoV-2. Secondary outcomes are any COVID-19-related event or intercurrent morbidities or death. Data will be collected by extracting serial blood samples and administering a questionnaire at the first face-to-face contact and monthly follow-up time points. The sample size estimated for this study is 1060. We will characterise the cohort, determine the seroprevalence rate of neutralising antibodies at baseline and determine the rates of antibody decline using a longitudinal mixed-effects model. Ethics and dissemination The Scientific Ethics Committee of the South Metropolitan Health Care Service approved the study protocol (Memorandum No 191/2021). We will present the results in two peer-reviewed publications and national and international professional and academic meetings. We will organise seminars with relevant stakeholders and hold town hall meetings with the local community. We will set up a COmmunity Cohort Study website at www.communitystudy.cl to disseminate the study purpose, research team and milestones.
引用
收藏
页数:8
相关论文
共 50 条
  • [1] SARS-CoV-2 humoral immune response in patients with cardiovascular risk factors: The COmmunity Cohort Study
    Bachelet, Vivienne C.
    Silva-Ayarza, Ignacio
    Navarrete, Maria S.
    MEDWAVE, 2024, 23 (11):
  • [2] Humoral Immune Response to SARS-CoV-2 in Iceland
    Gudbjartsson, Daniel F.
    Norddahl, Gudmundur L.
    Melsted, Pall
    Gunnarsdottir, Kristbjorg
    Holm, Hilma
    Eythorsson, Elias
    Arnthorsson, Asgeir O.
    Helgason, Dadi
    Bjarnadottir, Kristbjorg
    Ingvarsson, Ragnar F.
    Thorsteinsdottir, Brynja
    Kristjansdottir, Steinunn
    Birgisdottir, Kolbrun
    Kristinsdottir, Anna M.
    Sigurdsson, Martin I.
    Arnadottir, Gudny A.
    Ivarsdottir, Erna V.
    Andresdottir, Margret
    Jonsson, Frosti
    Agustsdottir, Arna B.
    Berglund, Jonas
    Eiriksdottir, Berglind
    Fridriksdottir, Run
    Gardarsdottir, Elisabet E.
    Gottfredsson, Magnus
    Gretarsdottir, Olafia S.
    Gudmundsdottir, Steinunn
    Gudmundsson, Kjartan R.
    Gunnarsdottir, Thora R.
    Gylfason, Arnaldur
    Helgason, Agnar
    Jensson, Brynjar O.
    Jonasdottir, Aslaug
    Jonsson, Hakon
    Kristjansson, Thordur
    Kristinsson, Karl G.
    Magnusdottir, Droplaug N.
    Magnusson, Olafur T.
    Olafsdottir, Lovisa B.
    Rognvaldsson, Solvi
    le Roux, Louise
    Sigmundsdottir, Gudrun
    Sigurdsson, Asgeir
    Sveinbjornsson, Gardar
    Sveinsdottir, Kristin E.
    Sveinsdottir, Maney
    Thorarensen, Emil A.
    Thorbjornsson, Bjarni
    Thordardottir, Marianna
    Saemundsdottir, Jona
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (18): : 1724 - 1734
  • [3] Cellular and humoral immune response to SARS-CoV-2 vaccination and booster dose in immunosuppressed patients: An observational cohort study
    Yang, Lu M.
    Costales, Cristina
    Ramanathan, Muthukumar
    Bulterys, Philip L.
    Murugesan, Kanagavel
    Schroers-Martin, Joseph
    Alizadeh, Ash A.
    Boyd, Scott D.
    Brown, Janice M.
    Nadeau, Kari C.
    Nadimpalli, Sruti S.
    Wang, Aileen X.
    Busque, Stephan
    Pinsky, Benjamin A.
    Banaei, Niaz
    JOURNAL OF CLINICAL VIROLOGY, 2022, 153
  • [4] Humoral response to SARS-CoV-2 vaccination in haemodialysis patients and a matched cohort
    Zhao, Tianchen
    Nishi-Uchi, Takamitsu
    Omata, Fumiya
    Takita, Morihito
    Kawashima, Moe
    Nishikawa, Yoshitaka
    Yamamoto, Chika
    Kobashi, Yurie
    Kawamura, Takeshi
    Shibuya, Kenji
    Kazama, Junichiro
    Shineha, Ryuzaburo
    Tsubokura, Masaharu
    BMJ OPEN, 2022, 12 (11):
  • [5] Isotyping and quantitation of the humoral immune response to SARS-CoV-2
    Goyins, Krystal A.
    Jieh-Juen Yu
    Papp, Sara B.
    Beddard, Rachel
    Murthy, Ashlesh K.
    Chambers, James P.
    Arulanandam, Bernard P.
    EXPERIMENTAL BIOLOGY AND MEDICINE, 2022, 247 (12) : 1055 - 1060
  • [6] Study in dynamics of postvaccine and postexposure humoral immune response to SARS-CoV-2
    Bozhkova, Martina
    Kalchev, Yordan
    Lengerova, Gergana
    Veliyanova, Tanya
    Kalfova, Teodora
    Petrov, Steliyan
    Pasha, Danyal
    Taskov, Hristo
    Mudjeva, Marianna
    JOURNAL OF IMAB, 2021, 27 : 100 - 102
  • [7] Humoral Response to SARS-CoV-2 in Hemodialysis Patients
    Steers, Nicholas J.
    KIDNEY INTERNATIONAL REPORTS, 2021, 6 (07): : 1761 - 1763
  • [8] The humoral immune response to SARS-CoV-2 mounts and is durable in symptomatic haemodialysis patients
    La Milia, Vincenzo
    Tonolo, Silvia
    Luzzaro, Francesco
    Bonato, Claudio
    Cavalli, Andrea
    Foglieni, Barbara
    Debiase, Consuelo
    Limardo, Monica
    Longhi, Selena
    Ravasi, Chiara
    Vigano, Sara
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2021, 36 (06) : 1132 - 1134
  • [9] Humoral immune response to SARS-CoV-2 vaccination in MS patients treated with rituximab
    Torgauten, H. M.
    Cox, R. J.
    Myhr, K. -M.
    Langeland, N.
    Onyango, T. B.
    Torkildsen, O.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 775 - 775
  • [10] HUMORAL IMMUNE RESPONSE TO SARS-COV-2 VACCINE IN RITUXIMAB-TREATED PATIENTS
    Flores-Fernandez, E.
    Vazquez-Gomez, I.
    Valera-Ribera, C.
    Andujar-Brazal, P.
    Valls-Pascual, E.
    Nogueira Coito, J. M.
    Martinez-Ferrer, A.
    Ybanez-Garcia, D.
    Alegre-Sancho, J. J.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 974 - 975